Briviact (Brivaracetam) Wins Approval to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients

UCB announced on 5/14/18 that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company's newest anti-epileptic drug (AED) Briviact (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizures in patients age four years and older.